Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock‐Ah Im, Debu Tripathy, Yen‐Shen Lu et al.|New England Journal of Medicine|2019Cited by 1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Yen‐Shen Lu, Fábio Franke et al.|The Lancet Oncology|2018Cited by 1k
Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatmentHeather Greenlee, Debu Tripathy|CA A Cancer Journal for Clinicians|2017Cited by 762
Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline UpdateJulienne E. Bower, Karen M. Mustian, Christina Lacchetti et al.|Journal of Clinical Oncology|2024Cited by 210
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, William E. Barlow et al.|Cancer Research|2021Cited by 88